Trial reportMedicine2025
Therapeutic effect and mechanism of sivelestat sodium on acute lung injury: A randomized controlled trial.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The S100A8/A9-NETosis feedback loop in sepsis: potential mechanisms, immune crosstalk, and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo observe the therapeutic effect of sivelestat sodium on acute lung injury and explore its mechanism.
methodsEighty-six patients with acute lung injury admitted from April 2022 to December 2023 were selected as the research objects. According to the principle of randomized control and single-blindness, they were randomly divided into the observation group (43 cases) and the control group (43 cases). The control group was given conventional symptomatic treatment, while the observation group was treated with sivelestat sodium on this basis. The mechanical ventilation, ICU stay, hospital stay, and 28-day mortality were compared between the 2 groups. The differences in pulmonary function, inflammatory factors, oxygenation index (PaO2/FiO2), and respiratory rate (RR) between the 2 groups were detected and compared.
resultsThe duration of mechanical ventilation, ICU stay, and hospitalization in the observation group were significantly shorter than those in the control group, while there was no difference in 28-day mortality between the 2 groups (P > .05). Before treatment, pulmonary function indexes were compared between the 2 groups (P > .05). On the 5th and 7th days of treatment, the vital capacity and maximum ventilation volume of the 2 groups were significantly increased compared with those before treatment, and the values of pulmonary function indexes in the observation group at the same time point were better than those in the control group (P < .05). Before treatment, the inflammatory factors, PaO2/FiO2, and RR in the 2 groups were compared (P > .05). On the 5th and 7th day after treatment, the tumor necrosis factor-α, interleukin-1β, RR, and intercellular adhesion molecule-1 (ICAM-1) in the 2 groups were significantly decreased compared with those before treatment, while the NOD-like receptors (NLR) family pyrin domain containing 6 (NLRP6) and PaO2/FiO2 were significantly increased. At the same time, the values of tumor necrosis factor-α, interleukin-1β, ICAM-1, and RR after decreased and NLRP6 and PaO2/FiO2 after increased in the observation group were better than those in the control group (P < .05).
conclusionSivelestat sodium can improve lung function, correct PaO2/FiO2, and promote rehabilitation in patients with acute lung injury, which may be related to the regulation of NLRP6, ICAM-1, and other inflammatory factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.